ISO 15189足以保证内部使用实验室自建检测符合IVDR要求
本文讨论欧盟体外诊断医疗器械法规(IVDR)对实验室自建检测(LDT)的监管要求,论证ISO 15189质量体系可覆盖IVDR对LDT的设计、制造与性能安全规范。文章分析LDT在低容量 niche 应用和新检测转化中的临床价值,并指出IVDR实施可能导致部分商业检测消失、LDT需求急增,需合理解读ISO 15189以应对。
要点
- IVDR监管器械的设计、制造与使用,但不监管使用器械的医疗服务。
- 无合适商业器械时实验室可用LDT,需满足IVDR第5.5条文件义务和附录I性能安全规范。
- ISO 15189等效质量体系下的开发与制造可覆盖IVDR对LDT的要求。
核心结论
- ISO 15189质量体系足以作为保证内部使用LDT高质量制造的工具,以满足IVDR的要求。
研究设计与样本
- 本文为综述性讨论,分析IVDR对LDT的监管框架与ISO 15189的覆盖关系,并选取案例说明LDT实施。
主要发现
- IVDR旨在实现基于风险和用途的透明验证、结果可追溯至唯一识别器械及上市后监督。
- LDT服务于特定临床需求,常为低容量 niche 应用或新检测/治疗的转化阶段。
- 部分商业检测可能随IVDR推行而消失,许多将急需LDT替代。
- IVDR的非预期附带损害包括非盈利 niche 应用丧失、成本增加和资源浪费。
关键数值与推荐
- IVDR第5.5条规定LDT的文件义务,附录I规定性能与安全规范。
- LDT需在ISO 15189等效质量体系下开发与制造。
临床怎么用
- 实验室在无合适商业器械时可依据IVDR第5.5条和附录I要求,在ISO 15189体系下开发内部使用LDT。
- 应合理解读ISO 15189以覆盖IVDR要求,并针对预期用途和/或设计进行相称的风险管理。
局限性
- LDT替代需求的工作量取决于商业检测的修改是否使其成为LDT,以及国家立法者和主管当局如何处理新权限与责任。
- 立法框架应考虑地方具体情况,利用现有框架减轻医疗系统负担和相关机会成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The EU In-Vitro Diagnostic Device Regulation (IVDR) aims for transparent risk-and purpose-based validation of diagnostic devices, traceability of results to uniquely identified devices, and post-market surveillance. The IVDR regulates design, manufacture and putting into use of devices, but not medical services using these devices. In the absence of suitable commercial devices, the laboratory can resort to laboratory-developed tests (LDT) for in-house use. Documentary obligations (IVDR Art 5.5), the performance and safety specifications of ANNEX I, and development and manufacture under an ISO 15189-equivalent quality system apply. LDTs serve specific clinical needs, often for low volume niche applications, or correspond to the translational phase of new tests and treatments, often extremely relevant for patient care. As some commercial tests may disappear with the IVDR roll-out, many will require urgent LDT replacement. The workload will also depend on which modifications to commercial tests turns them into an LDT, and on how national legislators and competent authorities (CA) will handle new competences and responsibilities. We discuss appropriate interpretation of ISO 15189 to cover IVDR requirements. Selected cases illustrate LDT implementation covering medical needs with commensurate management of risk emanating from intended use and/or design of devices. Unintended collateral damage of the IVDR comprises loss of non-profitable niche applications, increases of costs and wasted resources, and migration of innovative research to more cost-efficient environments. Taking into account local specifics, the legislative framework should reduce the burden on and associated opportunity costs for the health care system, by making diligent use of existing frameworks.
引用
- Vanstapel FJLA, Orth M, Streichert T, et al. ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation. Clin Chem Lab Med. 2023. PMID: 36716120. doi:10.1515/cclm-2023-0045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。